Get the Stockscreener App
3.18
2.58%
0.08
Adc Therapeutics Sa stock is traded at $3.18, with a volume of 1.18M.
It is up +2.58% in the last 24 hours and up +4.26% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$3.10
Open:
$3.12
24h Volume:
1.18M
Relative Volume:
1.50
Market Cap:
$357.75M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-1.078
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
+1.60%
1M Performance:
+4.26%
6M Performance:
+95.09%
1Y Performance:
+12.77%
1-Day Range:
$3.08
$3.235
1-Week Range:
$3.01
$3.24
52-Week Range:
$1.05
$3.97
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.18 | 364.50M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
ADC Therapeutics SA Approaches Psychological Resistance Level2025 Valuation Update & AI Powered Trade Plan Recommendations - thegnnews.com
ADC Therapeutics (NYSE:ADCT) Cut to Sell at Wall Street Zen - MarketBeat
Brokerages Set ADC Therapeutics SA (NYSE:ADCT) Target Price at $7.75 - MarketBeat
ADC Therapeutics SA Price Holds Above Key Fib LevelQuarterly Risk Review & Precise Trade Entry Recommendations - newsyoung.net
Equities Analysts Set Expectations for ADCT FY2025 Earnings - MarketBeat
Guggenheim Reiterates Buy Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
RSI + MACD Show Convergence for ADC Therapeutics SAPortfolio Return Report & Free Weekly Chart Analysis and Trade Guides - newsyoung.net
ADC Therapeutics (NYSE:ADCT) Issues Quarterly Earnings Results, Misses Expectations By $0.14 EPS - MarketBeat
Is ADC Therapeutics SA the Top Chart Pick This WeekMarket Volume Summary & Free Weekly Watchlist of Top Performers - beatles.ru
Is It Too Late to Sell ADC Therapeutics SAWeekly Stock Report & Low Drawdown Momentum Trade Ideas - beatles.ru
Real Time Data Flags Unusual Activity in ADC Therapeutics SAJuly 2025 Fed Impact & High Conviction Buy Zone Picks - metal.it
ADC Therapeutics Reports Q2 2025 Financial Results: Earnings Breakdown and Strategic Maneuvers - AInvest
ADC Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update - BioSpace
ADC Therapeutics S.A. (NYSE:ADCT) Q2 2025 Earnings Call Transcript - Insider Monkey
ADC Therapeutics 2025 Q2 Earnings Deeper Losses Amid Revenue Growth - AInvest
MACD Cross Could Confirm Trend in ADC Therapeutics SA2025 Biggest Moves & Real-Time Buy Signal Notifications - metal.it
ADC Therapeutics SA (ADCT) Q2 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... By GuruFocus - Investing.com Canada
ADC Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA (ADCT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
ADC Therapeutics targets $600M–$1B peak revenue potential for ZYNLONTA amid strategic refocus and cost cuts - MSN
Transcript : ADC Therapeutics SA, Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener
ADC Therapeutics SA reports results for the quarter ended June 30Earnings Summary - TradingView
ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
ADC Therapeutics Reports Second Quarter 2025 Financial Results - TradingView
Can ADC Therapeutics SA weather a recessionConsistent Triple Digit Profits - mustnews.co.kr
Using data models to predict ADC Therapeutics SA stock movementPortfolio Positioning Strategy With Timing - Newser
How to recover losses in ADC Therapeutics SA stockSafe Entry Screening with Data Backed Analysis - Newser
Can volume confirm reversal in ADC Therapeutics SASwing Trade Timing with Daily Forecast - Newser
Will ADC Therapeutics SA stock go up soonWeekly Hot Stocks Based on Volume Flow - Newser
Will ADC Therapeutics SA continue its uptrendFree Value Investing Picks With Stability - Newser
Pattern recognition hints at ADC Therapeutics SA upsideAlpha Trade Flow With Risk Calibration - Newser
Reversal Confirmed ADC Therapeutics SA Stock Rallies Above MALow Risk High Return Opportunities Identified - beatles.ru
Earnings visualization tools for ADC Therapeutics SAFree Weekly Return Pick Forecast Reports - Newser
Is ADC Therapeutics SA reversing from oversold territoryRSI and MACD Signal Summary with Trends - Newser
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025 - 富途牛牛
Bank of New York Mellon Corp Decreases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
What’s next for ADC Therapeutics SA stock pricePredictive Analytics for Equity Growth Potential - Newser
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - sharewise.com
What makes ADC Therapeutics SA stock price move sharplySmart Trade Mapping with Entry Details - Newser
Chondrosarcoma Market: Epidemiology, Pipeline Products, Companies Working, Delveinsight Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, As - Menafn
How strong is ADC Therapeutics SA company’s balance sheetCapitalize on emerging growth stocks - Jammu Links News
What is ADC Therapeutics SA company’s growth strategyGet alerts on high-potential stock breakouts - Jammu Links News
How volatile is ADC Therapeutics SA stock compared to the marketMaximize portfolio value with expert tips - Jammu Links News
Does ADC Therapeutics SA stock perform well during market downturnsGet daily updates on top-performing stocks - Jammu Links News
Should I hold or sell ADC Therapeutics SA stock in 2025Achieve rapid growth with smart investments - Jammu Links News
What institutional investors are buying ADC Therapeutics SA stockConsistent triple-digit returns - Jammu Links News
What is the dividend policy of ADC Therapeutics SA stockUnlock exclusive trading strategies for gains - Jammu Links News
ADC Therapeutics (ADCT) to Release Quarterly Earnings on Tuesday - Defense World
Is ADC Therapeutics SA stock overvalued or undervaluedGet daily updates on promising stocks - Jammu Links News
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):